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Extended lymphadenopathy causes more harm than benefit for those
undergoing pancreaticoduodenectomy
Despite decreasing perioperative mortality and the addition of adjuvant chemotherapy, survival for patients diagnosed
with pancreatic cancer remains appalling and largely unchanged over time. Previously in HPB, Prof. Murray Brennan
has referred to these incremental improvements as ‘little more than shuffling the deck chairs on the titanic’. Along
similar lines a proposed hypothesis to improve survival has been to consider extending the degree of nodal resection
given the high rates and prognostic significance of nodal involvement in patients with resectable pancreatic cancer. In
this issue of HPB, Orci et al. have performed a systematic review and meta-analysis of five randomised trials (n = 724)
comparing extended to standard lymphadenectomy with the aim of determining its true effect. The key finding was
that extended lymphadenectomy was associated with an increase in adverse peri-operative outcomes. In the long term
follow up, debilitating diarrhoea was observed if circumferential autonomic nerve dissection had been performed. No
benefit in survival was observed in patients with or without nodal involvement.
All five studies were methodologically sound, however there was some inter study variation in terms of clinical
management. In the standard group, only one or two studies included the LN 14 group, yet this would be considered
part of a standard lymphadenectomy for most contemporary HPB surgeons. However the potential effect of this varia-
tion would seem only to risk exacerbating any potential difference between the two groups. Nodal dissection in the
extended group did appear to be more standardised with 4 or 5 studies taking LN16, LN 8, LN14, LN9 group rou-
tinely. The application of adjuvant therapy was variable. Despite these variations, survival curves were consistent with
other modern series. It is worth examining the survival curves in more detail as they show that the curves for each
group are almost identical suggesting that the risk of type II error is low.
This study provides robust evidence that extended lymphadenectomy has no role in routine practice for patients
with resectable pancreatic cancer.
Saxon Connor
Cardiopulmonary exercise testing and fitness for liver resection
Cardiopulmonary exercise (CPEX) testing has gained considerable popularity in pre-operative assessment of patients
undergoing major surgery in a variety of specialties. The test at its most simple level involves placing a patient on a
bicycle and asking them to cycle against resistance up to their maximum limit of exertion while undergoing monitor-
ing. This allows assessment of cardiac ischemia by ECG, anaerobic threshold based on gas exchange and oxygen satu-
ration and other parameters such as maximum power output.
In this issue of HPB, Kasivisvanathan et al. from London, evaluated the usefulness of CPEX testing in patients
scheduled to undergo major liver resection. The study included 104 patients considered ‘high risk’ out of 218 sched-
uled to undergo liver surgery during the study period. 70% of patients studied experienced postoperative complica-
tions. Using multivariate analysis, the only variable which was associated with increased postoperative morbidity was
VO2 level at an anaerobic threshold of <10.2. This AT figure is similar to some other studies in different specialties
and should be viewed with some confidence. This may prove to be a useful value to help counsel patients about their
risk of surgery and this in itself is an important point. CPEX does not really tell us whether patients should have sur-
gery or not but what it can do is to help quantify the risk of surgery and help the patient reach a fully informed deci-
sion about whether to proceed or not. In terms of complications, it would be interesting to see a more complex
analysis of whether CPEX can predict resilience to unpredictable complications such as biliary sepsis or unexpected
perioperative haemorrhage.
Stephen J. Wigmore
What’s behind moving the needle?
The utility and value of minimally-invasive robotic pancreatic surgery (RPS) is catching attention worldwide. For pro-
ponents and skeptics alike, many questions arise about the future of RPS. One basic question is – “How long will it
take me to learn how to do a RPS procedure well?” In keeping with their reputation for innovation and leadership in
RPS, the University of Pittsburgh team offer data and guidelines to support a learning curve for robotic distal pancre-
atectomy (R-DP). They actually began doing R-DP in 2008, and that is very impressive. I know pundits will claim
purely laparoscopic DP was alive and well then, but that misses the point of advance. The Pittsburgh group, especially
Herb Zeh, Amer Zureikat and Jim Moser, worked extremely hard to move the needle. . .for all of us. Yes the R-DP
experience that we see says something, but more so, it was the inherent fuel that lit RPS across Whipple procedures,
central pancreatectomy, selective enucleations and RAMPS procedures. Others worldwide continued to push ahead,
especially Ugo Boggi. Moser would join our unit in Boston intent on transferring the Pittsburgh experience to another
high-volume pancreatic surgery center. He battled at every level from reluctants like me, across team training and
resource dedication. However, forthcoming publications will show that RPS can grow across able and talented centres.
Through cumulative summation techniques, Shakir et al. indicate that R-DP can reliably be learned by 40 cases. They
indicate the plateaus of learning and skill acquisition but, beware of the hidden caveats. Before attempting RPS, expert
and experienced pancreatic surgeons should have full laparoscopic capabilities, optimal deployment and ability with
the robotic platform. RPS is today’s iteration of minimally-invasive pancreatic surgery. Don’t let your expensive robot
purchased for other service lines sit idle. Engage it to HPB surgery, ask your specialty partners for help, and move
your needle.
Mark Callery
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